Glecaprevir 100 mg / pibrentasvir 40 mg [Mavyret]
RxNorm 1940705

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 1940705 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: glecaprevir 100 mg / pibrentasvir 40 mg [Mavyret].

The following semantic concepts and normalized strings are associated with this clinical entity:

SBDC
Glecaprevir 100 mg / pibrentasvir 40 mg [Mavyret]
AUI:9248163
View

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

SBDCPrescribable

Semantic Branded Drug Component (SBDC):
Glecaprevir 100 mg / pibrentasvir 40 mg [Mavyret]
(Atom ID: 9248163)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
glecaprevir 100 MG / pibrentasvir 40 MG [Mavyret]
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
1940705
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
9248163
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SBDC
Semantic Branded Drug Component (Ingredient + Strength + Brand Name)
Source Code
1940705
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Patient Education

Glecaprevir and Pibrentasvir


The combination of glecaprevir and pibrentasvir is used to treat certain types of chronic (long-term) hepatitis C infection (swelling of the liver caused by a virus) in adults and children 12 years of age and older who weigh at least 99 pounds (45 kilograms). It is also used to treat certain types of chronic hepatitis C infection in adults and children 12 years of age and older who weigh at least 99 pounds (45 kilograms) who have already received another medication to treat their hepatitis C infection. Glecaprevir is in a class of medications called HCV NS3/4A protease inhibitors. It works by decreasing the amount of hepatitis C virus (HCV) in the body. Pibrentasvir is in a class of medications called HCV NS5A inhibitors. It works by stopping the virus that causes hepatitis C to spread inside the body.
[Learn More]


* Please review the disclaimer below.